ASH 2020 Updates in CLL

Experts in the management of hematologic malignancies discuss various abstracts and data updates presented at the ASH (American Society of Hematology) 2020 Annual Meeting on chronic lymphocytic leukemia (CLL).

Data from the following clinical trials are discussed:

• Abstract 123: Ibrutinib (Ibr) Plus Venetoclax (Ven) First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study 

• Abstract 1318: Zanubrutinib in Combination with Venetoclax for Patients with Treatment Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and del(17p) Arm D of the SEQUOIA (BGB-3111-304) Trial

• Abstract 125: Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)

• Woyach Abstract 1305: Three-Year Follow-Up from a Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia

• Abstract 2216: Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Front-Line Treatment of Chronic Lymphocytic Leukemia (CLL)

• Abstract 544: Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

• Abstract 545: Safety and Efficacy of CD19-CAR T Cells in Richter’s Transformation after Targeted Therapy for Chronic Lymphocytic Leukemia